阿斯利康AstraZeneca plc (AZN) 2007年年度报告「LSE」.pdf

1、CONTACT INFORMATIONREGISTERED OFFICE AND CORPORATE HEADQUARTERS ADDRESSAstraZeneca PLC15 Stanhope GateLondon W1K 1LNUKTel:+44(0)20 7304 5000Fax:+44(0)20 7304 5151INVESTOR RELATIONS CONTACTSUK:as above or e-mailIRSweden:AstraZeneca ABSE-151 85 SdertljeSwedenTel:+46(0)8 553 260 00Fax:+46(0)8 553 290 0

2、0or e-mailIR US:Investor RelationsAstraZeneca Pharmaceuticals LP1800 Concord PikePO Box 15437WilmingtonDE 19850-5437USTel:+1(302)886 3000Fax:+1(302)886 2972REGISTRAR AND TRANSFER OFFICEEquiniti LimitedAspect HouseSpencer RoadLancingWest SussexBN99 6DAUKTel(freephone in the UK):0800 389 1580Tel(outsi

3、de the UK):+44(0)121 415 7033SWEDISH SECURITIES REGISTRATION CENTREVPC ABPO Box 7822SE-103 97 StockholmSwedenTel:+46(0)8 402 9000US DEPOSITARYJPMorgan Chase BankJPMorgan Service CenterPO Box 3408South HackensackNJ 07606-3408USTel(toll free in the US):888 697 8018Tel(outside the US):+1(201)680 6630AS

4、TRAZENECA.COMANNUAL REPORT ANDFORM 20-F INFORMATION 2007ASTRAZENECAThis Annual Report and Form 20-F Information is also available online at ANNUAL REPORT AND FORM 20-F INFORMATION 2007INTRODUCTION 01AstraZeneca and our year in brief 01Financial highlights 02Chairmans statement 04Chief Executive Offi

5、 cers review 05DIRECTORS REPORT 08Goals,strategy and performance measurement 09Business environment 13Business organisation 17 Board of Directors at 31 December 2007 18 Chief Executive Offi cer,delegation of authority and Senior Executive Team 20Our resources,skills and capabilities 21 Medicines 21

6、Research and development 23 R&D governance and portfolio management 27 Development pipeline at 31 January 2008 28 Sales and marketing 31 Intellectual property 33 Supply and manufacturing 33 People 35 Main facilities 37Corporate governance and managing risk 38Cardiovascular(CV)medicines 50Gastrointes